Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.
Jeffrey A. Meckler, insider at Indaptus Therapeutics

Jeffrey A. Meckler Insider Information

Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.

What is Jeffrey A. Meckler's net worth?

The estimated net worth of Jeffrey A. Meckler is at least $142,020.62 as of June 6th, 2022. Mr. Meckler owns 45,374 shares of Indaptus Therapeutics stock worth more than $142,021 as of July 2nd. This net worth evaluation does not reflect any other assets that Mr. Meckler may own. Additionally, Mr. Meckler receives an annual salary of $958,840.00 as CEO at Indaptus Therapeutics. Learn More about Jeffrey A. Meckler's net worth.

How old is Jeffrey A. Meckler?

Mr. Meckler is currently 55 years old. There are 3 older executives and no younger executives at Indaptus Therapeutics. Learn More on Jeffrey A. Meckler's age.

What is Jeffrey A. Meckler's salary?

As the CEO of Indaptus Therapeutics, Inc., Mr. Meckler earns $958,840.00 per year. Learn More on Jeffrey A. Meckler's salary.

How do I contact Jeffrey A. Meckler?

The corporate mailing address for Mr. Meckler and other Indaptus Therapeutics executives is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. Indaptus Therapeutics can also be reached via phone at (646) 374-8050 and via email at [email protected] Learn More on Jeffrey A. Meckler's contact information.

Has Jeffrey A. Meckler been buying or selling shares of Indaptus Therapeutics?

Jeffrey A. Meckler has not been actively trading shares of Indaptus Therapeutics during the past quarter. Most recently, 0 shares of the business's stock in a transaction that occurred on Saturday, July 2nd. Learn More on Jeffrey A. Meckler's trading history.

Who are Indaptus Therapeutics' active insiders?

Indaptus Therapeutics' insider roster includes Jeffrey Meckler (CEO), and Michael Newman (Director). Learn More on Indaptus Therapeutics' active insiders.

Are insiders buying or selling shares of Indaptus Therapeutics?

In the last year, Indaptus Therapeutics insiders bought shares 2 times. They purchased a total of 30,914 shares worth more than $116,990.35. In the last year, insiders at the sold shares 1 times. They sold a total of 5,870 shares worth more than $29,350.00. The most recent insider tranaction occured on June, 6th when CEO Jeffrey A Meckler bought 19,727 shares worth more than $51,882.01. Insiders at Indaptus Therapeutics own 3.3 % of the company. Learn More about insider trades at Indaptus Therapeutics.

Information on this page was last updated on 6/6/2022.

Jeffrey A. Meckler Insider Trading History at Indaptus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2022Buy19,727$2.63$51,882.0145,374View SEC Filing Icon  
11/18/2021Buy11,187$5.82$65,108.34View SEC Filing Icon  
See Full Table

Jeffrey A. Meckler Buying and Selling Activity at Indaptus Therapeutics

This chart shows Jeffrey A Meckler's buying and selling at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indaptus Therapeutics Company Overview

Indaptus Therapeutics logo
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Read More

Today's Range

Now: $3.13
Low: $2.61
High: $3.18

50 Day Range

MA: $2.54
Low: $1.94
High: $3.26

2 Week Range

Now: $3.13
Low: $1.89
High: $28.83

Volume

213,073 shs

Average Volume

312,292 shs

Market Capitalization

$25.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.